Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Gains from Investment Securities (2016 - 2025)

Cytosorbents (CTSO) has disclosed Gains from Investment Securities for 13 consecutive years, with $12.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities rose 1.92% year-over-year to $12.8 million, compared with a TTM value of $12.8 million through Sep 2025, up 1.92%, and an annual FY2024 reading of $12.3 million, up 1166.41% over the prior year.
  • Gains from Investment Securities was $12.8 million for Q3 2025 at Cytosorbents, up from $12.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $12.8 million in Q3 2025 and bottomed at $42499.0 in Q2 2022.
  • Average Gains from Investment Securities over 5 years is $5.6 million, with a median of $6.9 million recorded in 2021.
  • The sharpest move saw Gains from Investment Securities tumbled 95.45% in 2021, then surged 20661.69% in 2023.
  • Year by year, Gains from Investment Securities stood at $6.9 million in 2021, then skyrocketed by 37.6% to $9.5 million in 2022, then crashed by 89.71% to $974555.0 in 2023, then surged by 1166.41% to $12.3 million in 2024, then increased by 3.31% to $12.8 million in 2025.
  • Business Quant data shows Gains from Investment Securities for CTSO at $12.8 million in Q3 2025, $12.2 million in Q2 2025, and $46876.0 in Q1 2025.